Teacher Retirement System of Texas Has $17.34 Million Stake in Regeneron Pharmaceuticals, Inc. (REGN)

Teacher Retirement System of Texas lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,772 shares of the biopharmaceutical company’s stock after purchasing an additional 313 shares during the period. Teacher Retirement System of Texas’ holdings in Regeneron Pharmaceuticals were worth $17,336,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Oppenheimer & Co. Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 20.6% during the second quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock worth $3,441,000 after purchasing an additional 1,199 shares during the period. Dupont Capital Management Corp purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $220,000. Shell Asset Management Co. boosted its holdings in shares of Regeneron Pharmaceuticals by 24.1% during the third quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock worth $5,565,000 after purchasing an additional 2,999 shares during the period. Blair William & Co. IL boosted its holdings in shares of Regeneron Pharmaceuticals by 4.8% during the second quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock worth $841,000 after purchasing an additional 79 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 2.4% during the second quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock worth $56,580,000 after purchasing an additional 2,646 shares during the period. Institutional investors own 67.80% of the company’s stock.

In related news, Chairman P Roy Vagelos sold 15,191 shares of the company’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $470.15, for a total transaction of $7,142,048.65. Following the transaction, the chairman now directly owns 329,543 shares in the company, valued at approximately $154,934,641.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $450.00, for a total transaction of $900,000.00. Following the transaction, the director now owns 11,000 shares in the company, valued at $4,950,000. The disclosure for this sale can be found here. Insiders have sold a total of 76,651 shares of company stock worth $36,285,438 over the last quarter. 10.80% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Teacher Retirement System of Texas Has $17.34 Million Stake in Regeneron Pharmaceuticals, Inc. (REGN)” was published by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/16/teacher-retirement-system-of-texas-has-17-34-million-stake-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded up $1.50 during trading on Thursday, hitting $386.30. 753,700 shares of the stock were exchanged, compared to its average volume of 902,983. Regeneron Pharmaceuticals, Inc. has a 12-month low of $340.09 and a 12-month high of $543.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. The company has a market cap of $41,231.70, a P/E ratio of 33.32, a PEG ratio of 1.51 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The firm had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same period in the previous year, the firm posted $3.13 EPS. The business’s quarterly revenue was up 23.0% on a year-over-year basis. sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current year.

REGN has been the subject of several research analyst reports. UBS AG restated a “buy” rating and issued a $535.00 price objective (up from $489.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 4th. Citigroup Inc. raised their price objective on shares of Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the stock a “buy” rating in a report on Friday, August 4th. Canaccord Genuity set a $522.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Bank of America Corporation restated a “buy” rating and issued a $593.00 price objective (up from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Finally, Credit Suisse Group restated a “buy” rating and issued a $485.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, September 11th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $475.34.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply